Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 Formulations and Food Effect Study
NCT06478563Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of amycretin in obesity and Overweight (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve at Day 126. Started Jun 2024; status: completed.
02
Drugs
amycretin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06478563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478563.